Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NTQ6179 SAD in Healthy Participants
NCT07909837Phase 1Recruiting
- Sponsor
- Nanjing Chia-Tai Tianqing Pharmaceutical
- Start
- Apr 2026
- Primary completion
- Apr 2027
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in acromegaly comparing NTQ6179 (Single Ascending Dose) with NTQ6179 placebo (2 arms). Primary endpoint: Incidence of treatment-emergent adverse events (TEAEs), treatment-related TEAEs (TRAEs), and serious adverse events (SAEs) at 13 days. Started Apr 2026; status: recruiting.
02
Drugs
NTQ6179
03
Conditions
acromegaly
Beyond the preview
Go deeper on NCT07909837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07909837.